Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations

Area of Science:

• Hematology
• Immunology
• Biochemistry

Background:

• Hemophilia A is a genetic bleeding disorder caused by a deficiency in factor VIII coagulant activity (VIII:C).
• High-responding inhibitors against factor VIII are a significant complication, hindering effective treatment with factor VIII concentrates.
• The composition of factor VIII concentrates, particularly the presence of von Willebrand factor, may influence treatment outcomes in inhibitor patients.

Purpose of the Study:

• To investigate the impact of different factor VIII concentrates on inhibitor neutralization and VIII:C recovery in hemophilia A patients.
• To explore the potential role of von Willebrand factor in modulating the interaction between factor VIII inhibitors and factor VIII concentrates.
• To determine if factor VIII epitope variation exists between different commercially available concentrates.

Main Methods:

• Inhibitor plasma samples and IgG fractions from seven hemophilia A patients with inhibitors were tested.
• A panel of seven different factor VIII concentrates (five plasma-derived, two recombinant) was used for in vitro testing.
• Inhibitor titres and VIII:C recovery were measured using different concentrates to assess inhibitor neutralization.

Main Results:

• A significant difference in VIII:C recovery was observed depending on the factor concentrate used.
• In two patients, inhibitor titres varied widely based on the concentrate tested.
• Concentrates with higher amounts of von Willebrand factor showed less inhibitor neutralization and greater VIII:C recovery compared to highly purified concentrates.

Conclusions:

• Factor VIII inhibitors can exhibit differential reactivity with factor VIII molecules in various concentrates, indicating epitope variation.
• Von Willebrand factor may play a role in blocking the epitope targeted by certain factor VIII inhibitors, potentially those directed against the light chain.
• In vitro testing of inhibitor reactivity with a panel of concentrates is recommended for selecting optimal treatment strategies in inhibitor patients.